Quantoom Bioservices
ActiveFinancials · financial year 2023, full format
2024 annual accounts not yet filed, deadline passed on 31 July 2025 The financial year closed on 31 December 2024. The accounts are due at the latest 7 months after the close (Companies Code art. 3:10). 2 financial years without a filing since the last one filed. Source: NBB filings, as of 3 November 2026.
Annual accounts 2023 filed on 03-07-2024 PDF all 2 filings
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€35,527▲ 65.7%
2022 · -€103,505
Working capital
€52,468
2022 · -€42,005
Multi-year overview
2022 to 2023, 2 financial yearsOperating result
-€35,024
▲ 66.1%
2023
20222023
Net result
-€35,527
▲ 65.7%
2023
middle half of the sector
20222023
Equity
€52,468
2023
lowest quarter of the sector
20222023
Total assets
€59,035
▼ 10.8%
2023
lowest quarter of the sector
20222023
Debt
€6,567
▼ 93.9%
2023
20222023
Working capital
€52,468
2023
middle half of the sector
20222023
Solvency
88.9%
▲ 152.3pp
2023
highest quarter of the sector
20222023
Current ratio
8.99
▲ 8.38
2023
highest quarter of the sector
20222023
Return on assets (ROA)
-60.2%
▲ 96.1pp
2023
lowest quarter of the sector
20222023
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20222023
Operating result-€103,361--€35,024▲ 66.1%
Net result-€103,505within the sector's middle half--€35,527within the sector's middle half▲ 65.7%
Equity-€42,005below the sector's middle half-€52,468below the sector's middle half
Total assets€66,217below the sector's middle half-€59,035below the sector's middle half▼ 10.8%
Debt€108,222-€6,567▼ 93.9%
Working capital-€42,005below the sector's middle half-€52,468within the sector's middle half
Solvency-63.4%below the sector's middle half-88.9%above the sector's middle half▲ 152.3pp
Current ratio0.61below the sector's middle half-8.99above the sector's middle half▲ 8.38
Return on assets (ROA)-156.3%below the sector's middle half--60.2%below the sector's middle half▲ 96.1pp
above
within
below
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2023 is a loss of €35,024, smaller than the loss of €103,361 in 2022.
Balance-sheet composition
Equity and liabilities €59,035
Equity
€52,468
Debt
€6,567
Debt's share of the balance-sheet total is 11.1%.
Key figures and ratios
Debt to equity
0.13
ROE
-67.7%
Debt ≤ 1 year
€6,567▼
2022 · €108,222
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Annual accounts
| Line | 2022 | 2023 | Change |
|---|---|---|---|
| Other operating charges640/8 | €100 | €483 | ▲ 383% |
| Non-recurring operating charges66A | - | €50 | - |
| Gross operating margin9900 | -€103,261 | -€34,491 | ▲ 66.6% |
| Operating profit (loss)9901 | -€103,361 | -€35,024 | ▲ 66.1% |
| Financial charges65/66B | €144 | €504 | ▲ 250% |
| Recurring financial charges65 | €144 | €504 | ▲ 250% |
| Profit (loss) for the period before taxes9903 | -€103,505 | -€35,527 | ▲ 65.7% |
| Profit (loss) for the period9904 | -€103,505 | -€35,527 | ▲ 65.7% |
| Profit (loss) for the period to be appropriated9905 | -€103,505 | -€35,527 | ▲ 65.7% |
| Line | 2022 | 2023 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €66,217 | €59,035 | ▼ 10.8% |
| Current assets29/58 | €66,217 | €59,035 | ▼ 10.8% |
| Amounts receivable within one year40/41 | €6,763 | €26,867 | ▲ 297% |
| Trade receivables40 | - | €4,316 | - |
| Other amounts receivable41 | €6,763 | €22,551 | ▲ 233% |
| Cash at bank and in hand54/58 | €59,454 | €32,168 | ▼ 45.9% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €66,217 | €59,035 | ▼ 10.8% |
| Equity10/15 | -€42,005 | €52,468 | - |
| Contributions10/11 | €61,500 | €61,500 | = |
| Capital10 | €61,500 | €61,500 | = |
| Issued capital100 | €61,500 | €61,500 | = |
| Profit (loss) carried forward14 | -€103,505 | -€9,032 | ▲ 91.3% |
| Amounts payable17/49 | €108,222 | €6,567 | ▼ 93.9% |
| Amounts payable within one year42/48 | €108,222 | €6,567 | ▼ 93.9% |
| Trade debts44 | €52,222 | €6,567 | ▼ 87.4% |
| Suppliers440/4 | €52,222 | €6,567 | ▼ 87.4% |
| Other amounts payable47/48 | €56,000 | - | - |
| Line | 2022 | 2023 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | -€103,505 | -€35,527 | ▲ 65.7% |
| Operating cash flow (approximation) | -€103,505 | -€35,527 | ▲ 65.7% |
| Change in cash | - | -€27,286 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.